Retinset

Targetting Ophthalmic Therapeutics

Retinset

Retinset is aimed at designing a portfolio of medicines to treat ophthalmic-related pathologies induced by neurovascular degeneration.

Pipeline
  • BSL01 is our leading program and is planned to initiate a Phase I clinical trial in 2019 in Spain.